Becker's Healthcare September 12, 2024
Claire Wallace

The FDA has approved Johnson & Johnson’s Tremfya to treat adults with moderate to severe ulcerative colitis.

It is the first and only approved fully human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23, which is a driver...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
STAT+: Q&A: How the FDA is approaching AI in clinical trials and drug development
The number of AI medical devices has spiked in the past decade
American College of Radiology, FDA partner to expand AI access
The FDA Approved A Self-Administered Nasal Spray For The Flu. Here’s How It Compares To The Traditional Flu Shot
FDA Approves Exact Sciences' Cologuard Plus Non-Invasive Colorectal Cancer Screening Test

Share This Article